Page last updated: 2024-09-26

lysylproline

Description

lysylproline: third & fourth amino acid in substance P sequence [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Lys-Pro : A dipeptide formed from L-lysine and L-proline residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID171204
CHEMBL ID3321985
CHEBI ID74567
SCHEMBL ID2123083
MeSH IDM0117890

Synonyms (21)

Synonym
chembl3321985 ,
chebi:74567 ,
bdbm50049713
lysylproline
lys-pro
l-lysyl-l-proline
(2s)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carboxylic acid
SCHEMBL2123083
l-proline, 1-l-lysyl-
52766-27-5
kp
lysyl-proline
l-lys-l-pro
h-lys-pro-oh
AKOS030525562
lysine-proline dipeptide
lysine proline dipeptide
kp dipeptide
k-p dipeptide
Q27144743
DTXSID50967215

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1183271Inhibition of ACE (unknown origin)2014European journal of medicinal chemistry, Sep-12, Volume: 84CoMFA and CoMSIA analysis of ACE-inhibitory, antimicrobial and bitter-tasting peptides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]